8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Jan 6, 2026·SEC
China Pharma Holdings, Inc.(CPHI)Earnings, Financials & Key Ratios
CPHI•AMEX
$0.73
Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryLarge-scale generic drug manufacturers
AboutChina Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.Show more
- Revenue$4M-8.5%
- EBITDA-$2M+23.4%
- Net Income-$3M+32.7%
- EPS (Diluted)-0.74-174.1%
- Gross Margin-3.18%+92.7%
- EBITDA Margin-36.42%+16.3%
- Operating Margin-74.53%+26.4%
- Net Margin-76.91%+26.5%
- ROE0%+100.0%
CPHI Price & Volume
China Pharma Holdings, Inc. (CPHI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Corporate Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
Key Thesis Takeaways
- China Pharma Holdings faces a critical existential threat as its core generic pharmaceutical business model continues to erode, evidenced by a 13.4% year-over-year revenue decline in 2026Q1.
- The company's inability to maintain positive gross margins, which plummeted to -54.9%, suggests a fundamental failure in cost management and competitive positioning within the Chinese market.
- Investors should exercise extreme caution given the precarious liquidity position and the significant risk of asset impairment associated with the $38.7 million in goodwill currently on the balance sheet.
Verdict Logic
the company's inability to generate positive cash flow, combined with a current ratio of 0.28, indicates an imminent risk of insolvency that outweighs any potential speculative upside.
CPHI Growth Metrics
China Pharma Holdings, Inc. (CPHI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-14.71%
5 Years-17.53%
3 Years-20.03%
TTM-7.07%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.43%
Return on Capital
10 Years-21.21%
5 Years-30.39%
3 Years-28.16%
Last Year0%
CPHI Recent Earnings
China Pharma Holdings, Inc. (CPHI) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.04
—
Rev
$983.5B
—
Q2 2026
Apr 1, 2026Metric
Actual
Est
EPS
$0.04
—
Rev
$1M
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.17
—
Rev
$756,217
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.16
—
Rev
$1M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.04 | $983.5B |
| Q2 2026 | Apr 1, 2026 | $0.04 | $1M |
| Q4 2025 | Nov 12, 2025 | $0.17 | $756,217 |
| Q3 2025 | Aug 14, 2025 | $0.16 | $1M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for China Pharma Holdings, Inc. (CPHI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.73 | $2.31M | -0.98 | -8.49% | -76.91% | 0% | — | |
| $3.77 | $4.73M | -26.10 | — | — | -1.45% | — | |
| $0.99 | $3.22M | -1.47 | -70.11% | -33.27% | -28.25% | — | |
| $0.96 | $32.96K | -0.00 | -69.88% | -569.09% | -134.41% | — | |
| $3.67 | $263.23M | 11.12 | -31.8% | 21.61% | 10.62% | — | |
| $46.15 | $1.72B | -329.64 | 36.41% | -5.57% | -33.92% | — |
Compare CPHI vs Peers
China Pharma Holdings, Inc. (CPHI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CPHI SEC Filings & Documents
China Pharma Holdings, Inc. (CPHI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CPHI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CPHI Frequently Asked Questions
China Pharma Holdings, Inc. (CPHI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is China Pharma Holdings, Inc.'s revenue?
China Pharma Holdings, Inc. (CPHI) reported $4.0M in revenue for fiscal year 2025. This represents a 10547% increase from $0.0M in 2002.
How fast is China Pharma Holdings, Inc. growing?
China Pharma Holdings, Inc. (CPHI) saw revenue decline by 8.5% over the past year.
Is CPHI profitable?
China Pharma Holdings, Inc. (CPHI) reported a net loss of $3.5M for fiscal year 2025.
Dividend & Returns
What is CPHI's return on equity?
China Pharma Holdings, Inc. (CPHI) has a return on equity (ROE) of 0.0%. Negative ROE indicates the company is unprofitable.
What is China Pharma Holdings, Inc.'s free cash flow?
China Pharma Holdings, Inc. (CPHI) generated $0.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.